Elevance Health, Inc. $ELV Stock: Meeder Asset Management Inc. Increases Holdings

Meeder Asset Management Inc. raised its position in Elevance Health, Inc. (NYSE:ELV – Free Report) by 32.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,150 shares of the company’s stock after buying an additional 4,722 shares during the quarter. Meeder Asset Management Inc.’s holdings in Elevance Health were worth $7,446,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Meiji Yasuda Asset Management Co Ltd. purchased a new stake in shares of Elevance Health in the 2nd quarter worth about $2,086,000. Stoneridge Investment Partners LLC purchased a new position in shares of Elevance Health during the second quarter valued at about $970,000. State Street Corp increased its position in shares of Elevance Health by 1.3% during the second quarter. State Street Corp now owns 10,426,610 shares of the company’s stock valued at $4,032,283,000 after buying an additional 137,914 shares during the period. Farther Finance Advisors LLC raised its stake in Elevance Health by 27.1% in the third quarter. Farther Finance Advisors LLC now owns 11,826 shares of the company’s stock worth $4,598,000 after buying an additional 2,518 shares in the last quarter. Finally, State of Wyoming bought a new position in Elevance Health in the second quarter worth about $1,765,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have weighed in on the company. TD Cowen lifted their price objective on Elevance Health from $465.00 to $495.00 and gave the company a “buy” rating in a research report on Friday, October 23rd. Wall Street Zen raised Elevance Health from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Barclays raised their target price on Elevance Health from $469.00 to $472.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Royal Bank Of Canada lifted their price target on Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a research report on Thursday, October 22nd. Finally, UBS Group upped their price target on Elevance Health from $460.00 to $523.00 and gave the stock a “buy” rating in a research note on Thursday, October 22nd. Sixteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Elevance Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $458.91.

View Our Latest Stock Analysis on Elevance Health

Insider Buying and Selling

In related news, CFO Mark Kaye sold 10,584 shares of the firm’s stock in a transaction that occurred on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the completion of the transaction, the chief financial officer owned 19,919 shares of the company’s stock, valued at $8,766,949.47. This trade represents a 34.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Ratnakar Lavu sold 1,300 shares of Elevance Health stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $440.00, for a total value of $572,000.00. Following the transaction, the executive vice president owned 14,849 shares of the company’s stock, valued at $6,533,560. The trade was a 8.05% decrease in their position. The SEC filing for this sale provides additional information. 0.34% of the stock is owned by company insiders.

Elevance Health Trading Down 7.5%

NYSE:ELV opened at $401.40 on Thursday. Elevance Health, Inc. has a one year low of $274.84 and a one year high of $450.69. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.47. The company’s 50-day simple moving average is $416.91 and its 200 day simple moving average is $376.44. The firm has a market capitalization of $86.73 billion, a P/E ratio of 17.12, a PEG ratio of 2.07 and a beta of 0.63.

Elevance Health (NYSE:ELV – Get Free Report) last announced its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The business had revenue of $50.44 billion during the quarter, compared to the consensus estimate of $49.28 billion. During the same quarter last year, the firm earned $6.03 earnings per share. The business’s revenue for the quarter was up .7% on a year-over-year basis. As a group, analysts forecast that Elevance Health, Inc. will post 29.15 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be paid a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio is presently 29.34%.

Elevance Health Profile

(Free Report)

Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Further Reading

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.